March 2025, Vol 2, No 3
In a message issued on YouTube, Collins said that the goal is to reduce the staff to 398,000 employees from the agency’s current level of approximately 470,000 employees, which represents nearly a 15% decrease. Read More ›
What a way to begin March! At a time when federal healthcare is changing significantly, in large part due to President Donald Trump’s second nonconsecutive term election, AMSUS was perfectly timed. Read More ›
Officials with the Department of Veterans Affairs recently announced they will roll out 9 additional electronic health record systems (EHR), bringing the total to go live in 2026 to 13, with complete deployment of the EHR at all VA medical facilities as early as 2031. Read More ›
Like little kids on a road trip, those of us in healthcare keep asking about biosimilars, “are we there yet?” And like most parents, we keep saying, “soon.” Regular updates are important, however, to keep us engaged and motivated to make optimal use of these beneficial agents as they become available. Read More ›
In a first since the 1960s, methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder (PTSD) and alcohol use disorder among veterans will be the subject of a study being launched by Veterans Affairs (VA). Read More ›
Fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo) has been approved by FDA officials for use in patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, who have progressed on one or more endocrine therapies in the metastatic setting. Read More ›
In a statement released online, officials with TRICARE touted their Military Health System Nurse Advice Line. Read More ›
On January 17, 2025, the FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer. Read More ›
Tricare covers doses of vaccines and immunizations in accordance with the Centers for Disease Control and Prevention guidelines, and a recently issued statement1 encouraged physicians to encourage patients to get preventive health services, including vaccines, particularly against respiratory syncytial virus (RSV). Read More ›
The FDA has approved sotorasib (Lumakras; Amgen) with panitumumab (Vectibix; Amgen) for adult patients with KRAS G12C–mutated metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Read More ›